Fresenius SE & Co. (FSNUY) Stock Price, News & Analysis

Company Overview

Fresenius SE & Co. KGaA is a global healthcare group headquartered in Bad Homburg vor der Höhe, Germany. Founded in 1912 by Eduard Fresenius, the company has grown into one of the world’s leading providers of products and services for dialysis, hospitals and outpatient medical care. Trading on major European exchanges and available over the counter in the U.S. as FSNUY, Fresenius SE & Co. brings together a portfolio of specialized healthcare businesses under one corporate umbrella.

The company operates through four main business segments. Fresenius Medical Care is the largest provider of renal care products and services, including dialysis machines, disposables and clinic operations. Fresenius Kabi offers a broad range of lifesaving medicines, infusion therapies, clinical nutrition and medical devices for intravenous drug delivery. Fresenius Helios manages a network of acute care hospitals and outpatient facilities across Europe, while Fresenius Vamed specializes in planning, construction and management of healthcare projects and facilities, supporting clients from conception through operation.

Fresenius serves patients and healthcare providers in more than 100 countries, with production sites, research centers and clinical operations spanning Europe, North America, Asia-Pacific and Latin America. The company emphasizes continuous innovation, investing in research and development to enhance patient outcomes and streamline care delivery. Under the leadership of Chief Executive Officer Dr. Stephan Sturm, Fresenius pursues a strategy of geographic expansion and portfolio optimization to address evolving global healthcare needs.

Key Stats

• Today's Range: $12.86 to $12.98
• 50-Day Range: $10.40 to $12.99
• 52-Week Range: $10.33 to $33.93
• Volume: 57,495 shs
• Average Volume: 297,813 shs
• Market Capitalization: $29.02 billion
• P/E Ratio: 17.17
• Dividend Yield: 1.55%
• Price Target: N/A
• Consensus Rating: Buy

Fresenius SE & Co. Stock Analysis - MarketRank™

Fresenius SE & Co. scored higher than 60% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.7 / 5
• Analyst Rating: Buy

Consensus Rating

Fresenius SE & Co. has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Fresenius SE & Co. has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 9.80%

Earnings Growth

Earnings for Fresenius SE & Co. are expected to grow by 9.80% in the coming year, from $1.02 to $1.12 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Fresenius SE & Co. is 17.17, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 45.93.

Price to Earnings Ratio vs. Sector

The P/E ratio of Fresenius SE & Co. is 17.17, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 280.88.

Price to Book Value per Share Ratio

Fresenius SE & Co. has a P/B Ratio of 1.30. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.01% of the float of Fresenius SE & Co. has been sold short.

Short Interest Ratio / Days to Cover

Fresenius SE & Co. has a short interest ratio ("days to cover") of 0.33, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Fresenius SE & Co. has recently decreased by 31.39%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 2.5 / 5
• Dividend Strength: Moderate

Dividend Yield

Fresenius SE & Co. pays a meaningful dividend of 1.56%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Fresenius SE & Co. does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Fresenius SE & Co. is 26.67%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Fresenius SE & Co. will have a dividend payout ratio of 17.86% next year. This indicates that Fresenius SE & Co. will be able to sustain or increase its dividend.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for Fresenius SE & Co. this week, compared to 1 article on an average week.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Fresenius SE & Co. insiders have not sold or bought any company stock.

Percentage Held by Institutions

Fresenius SE & Co. has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 5/06/2026
• Today: 7/31/2026
• Next Earnings (Estimated): 8/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: OTCMKTS:FSNUY
• CIK: 904868
• Web: www.fresenius.com
• Phone: (496) 172-6080
• Fax: N/A
• Employees: 178,394
• Year Founded: 1912

Profitability

• EPS (Trailing Twelve Months): $0.75
• Trailing P/E Ratio: 17.17
• Forward P/E Ratio: 12.63
• P/E Growth: N/A
• Net Income: $1.43 billion
• Net Margins: 6.55%
• Pretax Margin: 9.49%
• Return on Equity: 10.09%
• Return on Assets: 4.72%

Debt

• Debt-to-Equity Ratio: 0.41
• Current Ratio: 1.27
• Quick Ratio: 0.98

Sales & Book Value

• Annual Sales: $25.87 billion
• Price / Sales: 1.12
• Cash Flow: $1.55 per share
• Price / Cash Flow: 8.31
• Book Value: $9.93 per share
• Price / Book: 1.30

Miscellaneous

• Outstanding Shares: 2,252,950,000
• Free Float: N/A
• Market Cap: $29.02 billion
• Optionable: Not Optionable
• Beta: 0.63